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Background. Differences in oral human papillomavirus (HPV) prevalence and contrasts in HPV-attributable fractions (AFs) in 
oropharyngeal cancer (OPC) have not been evaluated in depth.
Methods. A systematic review was performed to identify studies in which at least 50 healthy individuals were tested for oral 
HPV infection. Information on sex, age, tobacco/alcohol consumption, sex practices, specimen collection, HPV detection, and pop-
ulation type was extracted. Prevalences were pooled using random-effects models for meta-analyses of binomial data. Correlations 
were assessed by the Spearman test.
Results. Forty-eight reports comprising 28 544 individuals fulfilled inclusion criteria. Global oral HPV prevalence was 4.9%. 
Estimates were highest in Europe, although regional differences were not statistically significant. HPV16 prevalence was 1.0% glob-
ally, and regional differences became statistically significant. A lifetime history of >6 sex partners showed a higher risk of oral HPV 
infection. The age-specific HPV distribution revealed a prevalence of ≥5% over 40 years of age and a lower prevalence at younger 
ages. There was no association between oral HPV prevalence and HPV-AFs or age-standardized rates (ASRs) of OPC, genital HPV 
in healthy women, or tobacco use.
Conclusions. Differences in HPV-AFs or ASRs of OPC cannot be explained by differences in the prevalence of oral HPV infec-
tion across healthy populations. Consistent research on determinants of oral HPV prevalence, acquisition, clearance, and persistence 
is warranted.
Keywords. Oral; HPV infection; healthy population; head and neck cancer; meta-analysis.
Persistent oral human papillomavirus (HPV) infection is thought 
to be causally linked to the increasing rates of oropharyngeal cancer 
(OPC) in some regions of the world [1–5]. These rising trends have 
been observed in regions where tobacco consumption decreased 
[6] while the lifetime number of sex partners and the proportion 
of people with a history of performing oral sex increased over time 
[7–9]. HPV-attributable fractions (AFs) in cases of OPC are very 
heterogeneous, with the highest HPV-AFs observed in the United 
States and Northern Europe, young patients, and recent calendar 
periods [10–14]. Sex differences are also observed, with higher 
HPV-AFs in males or females, depending on the region [10–16].
Contrary to the high number of prevalence surveys on cer-
vical HPV infection conducted in the past 20 years, equivalent 
surveys on oral HPV infection prevalence in healthy individu-
als are scarce. The first global estimate on the prevalence of oral 
infection derives from a systematic review published in 2010 
[17] that conducted a simple pooling of 18 studies involving 
4581 cancer-free subjects with an estimated overall oral HPV 
prevalence of 4.5%. The most frequently detected HPV type 
was HPV16 (1.3%). Two more recent systematic reviews with 
meta-analyses aimed to evaluate risk factors for oral HPV in-
fection [18] and to synthesize data on the prevalence, incidence, 
clearance, and persistence of oral HPV infection in healthy pop-
ulation [19]. The estimated prevalences of oral HPV infection 
overall and due to HPV16 were 5.5% and 1.0%, respectively 
[18], and 7.7% and 1.4%, respectively [19]. All of those reviews 
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included high-risk populations, such as female sex workers and 
sexually transmitted diseases clinic attendees [17, 18] or men 
who have sex with men and women who had gynecological 
lesions [18, 19], and had several limitations, such as the ina-
bility to provide age-specific prevalence and the underrepre-
sentation of regions such as Asia, Latin America, and Africa. 
Moreover, none of the studies evaluated in detail the epidemio-
logical differences in oral HPV infection across populations and 
the extent to which such differences can explain differences in 
HPV-AFs in OPC.
Therefore, we aimed to conduct a new systematic review 
applying sound meta-analysis techniques to provide age-, sex-, 
and type-specific global and regional estimates of the prevalence 
of oral mucosal alpha-type HPV infection in healthy individu-
als and to evaluate the potential influence and predictive value 
of oral HPV infection in healthy individuals on the estimated 
HPV-AFs and of OPC age-standardized rates (ASRs) at regional 
and national levels once differences in potential cofactors were 
considered.
METHODS
Search Strategy, Selection Criteria, and Data Extraction
The National Institutes of Health PubMed and Scopus search 
engines were used to identify articles that reported results of 
HPV testing of oral specimens collected from healthy individ-
uals. Search criteria involved publication from 1 January 1995 
through 19 May 2015 and the keywords “oral” AND (“papil-
lomavirus” OR “HPV”). All articles reporting data on oral 
HPV prevalence in healthy individuals were selected. PRISMA 
(Preferred Reporting Items for Systematic Reviews and 
Meta-analyses), MOOSE (Guidelines for Meta-analyses and 
Systematic Reviews of Observational Studies), and GATHER 
(Guidelines for Accurate and Transparent Health Estimates 
Reporting) checklists were followed [20–22]. The following 
exclusion criteria were used: studies involving subjects vacci-
nated against HPV, individuals with HPV-related pathology, 
and other high-risk populations (ie, prostitutes, drug users, 
partners of individuals of any HPV-related pathology, men who 
have sex with men, immunosuppressed populations, individ-
uals recruited in sexually transmitted clinics); studies involv-
ing pregnant women or infants and children (age ≤13  years); 
studies that had HPV test results for <50 subjects and did not 
use DNA-based HPV testing methods; studies that did not 
provide information on the sex distribution of participants; 
commentaries; and systematic reviews. Cross-references were 
also reviewed to identify additional sources. When duplicate 
reports were identified, the one that had the largest sample size 
or presented more-detailed information was selected. For stud-
ies including multiple geographic locations, the data were sepa-
rated by country, if possible.
Data were extracted by 2 investigators (M. M. and M. T.) inde-
pendently and then reviewed by 2 investigators (L. B. and L. A.) 
for discrepancies. Covariates and categorization are described 
in Supplementary Table 1a. When possible, separate data on 
overall and type-specific HPV positivity were extracted by sex, 
country, age group, tobacco and alcohol consumption, oral sex 
practice, and lifetime number of sex partners. Additionally, 
authors were contacted to provide information on overall and 
type-specific HPV prevalence, disaggregated by sex and age 
groups, if such information was not included in the publication.
Statistical Analyses
We primarily focused on mucosal alpha-type HPV for overall 
estimates of oral infection, given the low prevalence of nonal-
pha types detected in head and neck cancer (HNC) [23, 24]. 
Thus, the estimation of the prevalence of cutaneous and non-
alpha oral HPV infection was performed as a secondary objec-
tive of the meta-analysis. Overall oral HPV DNA prevalence 
includes all individuals with positive results of a broad-spec-
trum alpha-mucosal HPV DNA test. High-risk oral HPV DNA 
prevalence data comprised HPV DNA–positive cases involving 
≥1 established high-risk type (ie, HPV16/18/31/33/35/39/45/5
1/52/56/58/59) [25]. The HPV DNA type–specific prevalence 
was estimated for types 6, 11, 16, 18, 26, 31, 33, 34, 35, 39, 40, 
42, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 
71, 72, 73, 81, 82, 83, 84, and 89 by dividing the number of 
cases positive for a specific type by the total number of cases 
tested for the specific type. Meta-analyses were conducted using 
metaprop, a statistical procedure in Stata 15, developed at the 
Unit of Cancer Epidemiology (Sciensano, Brussels) [26]. A ran-
dom-effects model including Freeman-Tukey arcsine transfor-
mation of the prevalence was used to normalize variance. 95% 
confidence intervals (CIs) were computed around study-spe-
cific and pooled prevalences, based on the score-test statistic. 
The percentage of total variation because of interstudy heter-
ogeneity was evaluated with the I2 measure [27]. Sample size 
effects were evaluated by visual inspection of funnel plots, and 
plot asymmetry was assessed formally with the Egger test with 
R (version 3.2.3) [28]. A sample size calculation established 500 
as the minimum number of tested individuals needed to pro-
duce an estimate. The data available from studies did not allow 
estimation of the prevalence of multiple infections. Countries 
were classified by income level, according to the United Nations 
classification [29]. Age-specific prevalences were transformed 
into 10-year age groups. Intrastudy relative risks (RRs) were 
pooled with the metan command in Stata 15 [30]. We planned 
to perform subgroup meta-analyses and meta-regression to ex-
plain interstudy heterogeneity [31] (Supplementary Figure 1). 
However, exploratory analyses using linear or logistic models 
revealed its unfeasibility because of the lack of data equally 
stratified for multiple covariates. Correlation analyses between 
our estimates of oral HPV infection and HPV-AFs in OPC 
[12, 13, 32, 33], ASRs of OPC in 2018 [34], and HPV-related 
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unpublished data), and tobacco use in 2006 [6] were explored 
with the Spearman and Kendall τ tests.
RESULTS
A total of 2577 abstracts from the National Institutes of Health 
PubMed search engine and 2728 from the Scopus search engine, 
published between 1 January 1995 and 19 May 2015, were iden-
tified with the search strategy. After removing duplicates, 3226 
abstracts were reviewed for inclusion, and 181 full-text articles 
were assessed for eligibility. A total of 56 studies were initially 
evaluated (Supplementary Figure 2). However, when perform-
ing the analysis by type of study, a statistically significant much 
higher overall oral HPV prevalence was obtained for studies in 
which subjects were controls unmatched to patients with can-
cer, as compared to studies in which subjects were age-matched 
controls, or individuals from a general population who were 
recruited in population-based surveys (Supplementary Figure 
3). A sensitivity analysis was then performed by excluding the 
8 studies in which individuals were unmatched controls, and 
these studies were excluded for further analyses because this 
group might be nonrepresentative of the general population. 
Thus, 48 studies contributing data for 28 544 healthy individu-
als were considered for the final analyses (Supplementary Table 
2).
The estimated overall oral HPV prevalence of alpha muco-
sal types worldwide was 4.9% (95% CI, 3.7%–6.1%), with 1477 
individuals positive for oral HPV infection, and ranged from 
0.0% (95%CI .0%–3.7%) to 24.1% (95%CI 18.2%–31.1%). High 
heterogeneity was observed (I2  =  94.7%; P  <  .001). Estimates 
were highest in Europe (6.5% [95% CI, 3.4%–10.5%]; 142 of 
1967 individuals), followed by North America (5.1% [95% CI, 
3.6%–6.8%]; 928 of 15 324 individuals), Latin America (4.6% 
[95% CI, 2.2%–6.7%]; 320 of 6635 individuals), and Asia (3.1% 
[95% CI, .7%–6.8%]; 58 of 3849 individuals), although differ-
ences between regions were not statistically significant (Figure 
1A). Restriction of the analysis to high-risk HPV types revealed 
a prevalence of 2.6% (95% CI, 1.7%–3.5%; 686 of 23 286 indi-
viduals) globally (Figure 1B).
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Figure 1. Prevalence of oral human papillomavirus (HPV) infection overall (A), due to high-risk types (B), and due to HPV16 (C), by region. Regional estimates and hetero-
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HPV16 was the most common type in all regions, with a 
worldwide prevalence of 1.0% (95% CI, .6%–1.5%; 242 of 23 866 
individuals), and differences between regions were statistically 
significant (Figures 1C and 2). The next-most-common types 
were substantially less frequent and varied by region.
Figure 3 shows the pooled overall prevalence of oral HPV infec-
tion, stratified by country. Studies with the highest number of par-
ticipants came from the United States, Costa Rica, and China. In the 
subregional analysis, Southern Europe was noted as the subregion 
with the highest overall estimates (9.5% [95% CI, 3.3%–18.1%]; 
P < .001; Table 1 and Supplementary Figure 5). In the analysis strati-
fied by income, high-income regions showed a higher HPV16 HPV 
prevalence than middle-income regions (P = .048), whereas low-in-
come regions were not represented in this meta-analysis (Table 1).
The prevalence of cutaneous and oral nonalpha HPV infec-
tion was lower than that of mucosal types, with estimated val-
ues of 1.8% (95%CI .6%–3.6%; based on 12 studies) and 0.7% 
(95%CI .1%–1.9%; based on 5 studies), respectively.
Age-specific information on the oral overall HPV prevalence 
was available for 27 publications contributing data for 11  493 
individuals. The age group of <30 years had the highest number 
of observations (Figure 4). The age group of 50–59 years showed 
the highest prevalence estimates (7.5% [95%CI 4.8%–10.5%]), and 
observed differences between age groups were statistically signifi-
cant (P = .002).
Table 1 summarizes estimates of the prevalence of oral infec-
tion overall, due to high-risk HPV types, and due to HPV16, 
stratified by select variables. HPV16 estimates differed by 
study design, with case-control studies having higher estimates 
than other designs. The highest overall HPV prevalence was 
observed in studies with the highest proportion of smokers in 
the sample. Statistically significant differences between esti-
mates for all types, high-risk types, and HPV16, stratified by 
the proportion of participants who performed oral sex, were 
also observed. Finally, higher estimates of the overall preva-
lence of infection were noted when the when mean age of 
the study population was 25–39  years or >55  years as com-
pared to <25 or >39  years. Other variables, such as last year 
of testing, proportion of male participants, or proportion of 
participants with a high lifetime number of sex partners, did 
not show statistically significant differences in the prevalence 
of oral infection overall, due to high-risk HPV types, or due to 
HPV16. Twenty-seven of 48 studies presented information on 
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of oral HPV infection in men and women was similar, with 
worldwide estimates of 4.3% (95%CI 2.7%–6.4%) and 3.8% 
(95%CI 2.6%–5.2%), respectively. When stratifying by type 
of study (ie, studies including only men, only women, or both 
sexes), estimates were similar, with the exception of slightly 
higher estimates in women for studies only testing women 
(Supplementary Table 3). Men in North America had double 
the risk of oral HPV infection as compared to women (RR, 2.0 
[95%CI .99–4.0]; Table 2). A history of tobacco consumption 
was associated globally with a higher risk of oral HPV infec-
tion (RR, 1.4 [95% CI, .9–2.4]), although this association did 
not reach statistical significance. An increased RR for having a 
high versus low lifetime number of sex partners was observed 
globally (2.27 [95%CI 1.34–3.85]) but not for ever performing 
versus never performing oral sex.
Sample size effects, suggestive of publication bias, were 
observed, with a higher prevalence of infection reported in 
smaller studies (Supplementary Figures 8 and 9). Correlation 
analyses between the prevalence of oral infection overall, due 
to high-risk types, or due to HPV16 and HPV-AFs in OPC, 
ASRs of OPC in 2018, and HPV-related HNC in 2012, genital 
HPV in healthy women, and tobacco use, stratified by country 
or region, did not show any correlation pattern (Figure 5 and 
Supplementary Table 4).
DISCUSSION
We are the first to present data on the prevalence of oral HPV 
infection with respect to several covariates, including age group, 
in healthy individuals. We used strict inclusion criteria to obtain 
a sample as representative as possible of the general population 
and to avoid bias and reduce heterogeneity. The most-appropri-
ate meta-analytical techniques [26] were chosen, to provide ro-
bust estimates of oral HPV prevalence in the general populations. 
Associations between oral HPV and HPV AFs in OPC, ASRs of 
OPC in 2018, and HPV-related HNC in 2012, genital HPV in 
healthy women, or tobacco use, stratified by country and region, 
were explored for the first time with correlation analyses.
Globally, we estimated the prevalence of alpha mucosal oral 
HPV infection among healthy individuals to be 4.9% overall 
and the prevalences due to high-risk HPV and HPV16 to be 
2.6% and 1.0%, respectively. HPV16, which is present in >90% 
of HPV-driven OPCs, was the most frequent type everywhere 
and the only one presenting statistically significant differences 
between regions, with Europe presenting the highest esti-
mates. The age-specific prevalence presented a sigmoid pat-
tern, reaching its peak among individuals aged 50–59  years. 
Differences in the prevalence oral HPV infection stratified by 
sex were observed only in North America. Having a high life-
time number of sex partners showed an increased RR for having 
oral HPV infection, but having a history of performing oral sex 
did not.
Correlation analyses did not show any association between 
oral HPV and HPV-AFs in OPC, ASRs of OPC, and HPV-
related HNC, genital HPV in healthy women, or tobacco use.
Global estimates were similar to those of earlier systematic 












Figure 3. Distribution of studies on the overall prevalence of oral human papillomavirus (HPV) infection, by country. Each square corresponds to a study included in the 
meta-analysis. The size of the squares is proportional to the size of the study. The distribution of the squares within each country is arbitrary and does not correspond to the 
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Oral HPV Prevalence, % (95% CI)
Overall Pc
High-Risk 
Types Pc HPV16 Pc
Overall 48 28 544 4.9 (3.7–6.1) 2.6 (1.7–3.5) 1.0 (.6–1.5)
Region   P-valuec = .522  P-valuec = .064  P-valuec = .003
 Latin America 11 6635 4.6 (2.2–7.7)  1.9 (.9–3.3)  0.6 (.1–1.3)  
 North America 16 15 324 5.1 (3.6–6.8)  3.6 (2.3–5.3)  1.1 (.4–2.1)  
 Asia 6 3849 3.1 (.7–6.8)  0.9 (.1–2.5)  0.2 (.0–.4)  
 Europe 13 1967 6.5 (3.4–10.5)  3.6 (.6–8.3)  2.7 (.7–5.7)  
Subregion   P-valuec = .001  P-valuec = .001  P-valuec = .045
 North America 16 15 324 5.1 (3.6–6.8)  3.6 (2.3–5.3)  1.1 (.4–2.1)  
 Central America 4 4051 6.6 (3.5–10.7)  3.0 (1.0–5.9)  1.2 (.2–3.2)  
 South America 6 1474 4.4 (.6–10.9)  0.9 (.0–2.7)  0.1 (.0–.7)  
 Americasd 1 898 0.2 (.1–.8)  …  …  
 Eastern Asia 2 3197 0.6 (.3–.9)  0.5 (.3–.7)  0.4 (.2–.6)  
 Southern Asia 3 580 2.7 (.2–7.3)  …  …  
 Northern Europe 5 978 4.9 (.9–11.5)  3.3 (.0–11.0)  2.3 (.0–7.6)  
 Southern Europe 5 579 9.5 (3.3–18.1)  …  …  
Income   P-valuec = .552  P-valuec = .087  P-value = .048
 High income 31 18 171 5.2 (3.8–6.7)  3.3 (2.0–4.9)  1.4 (.7–2.3)  
 Upper middle income 16 8959 5.3 (3.1–8.0)  1.8 (1.0–2.8)  0.5 (.2–1.0)  
 Lower middle income 2 516 2.4 (.0–7.5)  …  …  
Study population   P-valuec = .516  P-valuec = .833  P-valuec = .827
 Age-matched controls 14 6782 5.4 (3.0–8.3)  2.8 (1.1–5.1)  1.1 (.1–2.8)  
 Convenient samples from general 
population
14 4686 3.8 (2.6–5.2)  2.1 (1.1–3.3)  0.9 (.3–1.7)  
 Convenient samples from outpatients 14 4072 5.8 (2.8–9.7)  2.6 (.6–5.7)  1.1 (.1–2.8)  
 General population 7 13 004 4.8 (1.7–9.2)  3.2 (1.0–6.7)  0.7 (.3–1.3)  
Study design   P-valuec = .332  P-valuec = .057  P-valuec = .020
 Case-control 9 2967 4.8 (1.4–9.9)  4.3 (1.1–9.3)  1.5 (.0–5.5)  
 Clinical trial 1 2926 5.4 (4.6–6.2)  1.5 (1.1–2.0)  0.4 (.2–.7)  
 Cohort 11 8020 3.6 (2.1–5.4)  3.0 (1.2–5.4)  1.0 (.4–1.9)  
 Cross-sectional 28 14 631 5.5 (4.0–7.2)  2.1 (1.1–3.3)  0.8 (.4–1.5)  
Male sex, %   P-valuec = .439  P-valuec = .089  P-valuec = .107
 0–5 7 4309 5.1 (3.3–7.3)  1.4 (1.0–1.8)  0.3 (.1–.6)  
 6–50 17 4303 4.2 (2.1–6.9)  3.7 (.7–8.5)  1.8 (.0–5.4)  
 51–95 15 13 192 6.5 (4.4–9.1)  3.9 (.6–9.6)  2.2 (.0–9.8)  
 >95 9 5643 4.2 (2.2–6.8)  2.6 (1.1–4.6)  0.9 (.3–1.7)  
Tobacco use, %    P-valuec = .029  P-valuec = .668  P-valuec = .953
 6–50 20 17 325 6.0 (4.5–7.8)  3.1 (1.9–4.5)  1.0 (.6–1.6)  
 51–95 9 4428 7.0 (2.7–13.1)  2.3 (.3–5.8)  0.8 (.0–2.8)  
 Unknown 21 6691 3.2 (2.0–4.7)  2.0 (.7–3.9)  1.1 (.2–2.4)  
Alcohol use, %    P-valuec = .565  P-valuec = .934  P-valuec = .578
 6–50 9 4704 4.3 (1.4–8.6)  2.1 (.4–4.8)  0.5 (.0–1.5)  
 51–95 8 1678 6.4 (3.1–10.7)  2.6 (.2–7.0)  0.8 (.0–4.1)  
 Unknown 32 22 031 4.4 (3.3–5.6)  2.4 (1.5–3.4)  1.0 (.5–1.5)  
Oral sex performance, %    P-valuec = .001  P-valuec = .001  P-valuec = .043
 0–5 1 2535 0.7 (.4–1.0)  0.6 (.3–.9)  0.4 (.2–.7)  
 6–50 5 3548 7.3 (2.8–13.6)  3.6 (.4–9.5)  1.6 (.0–7.2)  
 51–95 10 11 673 5.7 (3.6–8.3)  4.7 (1.9–8.4)  1.0 (.3–2.3)  
 Unknown 34 10 788 4.5 (3.2–6.1)  2.1 (1.2–3.2)  0.9 (.4–1.6)  
High lifetime no. of sex partners, %    P-valuec = .161  P-valuec = .074  P-valuec = .352
 6–50 4 1307 6.5 (4.1–9.5)  4.7 (.5–12.6)  0.6 (.0–1.7)  
 51–95 3 9833 8.6 (3.9–14.8)  6.1 (2.6–10.8)  3.1 (.2–8.5)  
 Unknown 41 17 404 4.5 (3.2–5.9)  2.1 (1.3–3.0)  0.9 (.4–1.6)  
Collection method    P-valuec = .754  P-valuec = .350  P-valuec = .361
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However, our estimates are substantially lower than the most 
recently published estimate of 7.7% [19].
In agreement with Kreimer et al [17], we observed a similar 
overall prevalence for men and women. However, Shigeishi et al 
[18] and Tam et  al [19] found a higher oral HPV prevalence 
in men than in women, as was observed in the US popula-
tion-based National Health and Nutrition Examination Survey 
(NHANES) [35, 36], which represents the most robust estimate 
of oral HPV prevalence presented to date. Repeatedly, estimates 
from the United States have been generalized to the global 
population, because the most relevant insights of HPV-related 
OPC natural history mainly come from the United States [37]. 
Indeed, the United States contributed 52% of individuals in-
cluded in the meta-analysis (Figure 3). Discrepancies on HPV 
prevalence with respect to sex between the US and global esti-
mates are also observed in OPC [11, 12, 15].
Such discrepancies could be partially explained by differences 
in exposure to other risk factors, such as tobacco and alcohol 
use, or to differences in sexual behavior [14], as well as by other 
differences between studies. However, after exploring several 
meta-analytical strategies (Supplementary Figure 2), we could 
not adjust prevalence estimates by means of meta-regression, 
because of a lack of statistical power. Many studies defined 
and stratified covariates unequally, and few reported thor-
oughly stratified data. This is a general limitation inherent to 
meta-analyses of aggregated data extracted from published 
studies. To address this limitation, a meta-analysis of individual 
participant data should be performed.
If our results were accurate, immunological differences due 
to previous exposure to anogenital HPV infection or to differ-
ences in transmission effectiveness from men to women versus 
women to men could also explain the observed differences. A 
US study examining sex-based differences in risk factors for oral 
HPV infection observed that men but not women had a higher 
risk of HPV infection as the number of recent oral sex partners 
increased, whereas women but not men had a decreased risk of 
oral HPV infection as the lifetime number of vaginal sex part-
ners increased [38]. Correlation analyses were performed to ex-
plore these hypotheses, as well as whether differences in HPV 
AFs or ASRs in OPC or HPV-related HNC could be explained 
by differences on oral HPV prevalence across healthy popu-
lations. However, we did not find any significant correlation 
suggesting that the observed differences were due to methodo-






Oral HPV Prevalence, % (95% CI)
Overall Pc
High-Risk 
Types Pc HPV16 Pc
 Oral rinse 9 5139 4.2 (2.4–6.4)  2.4 (1.0–4.3)  1.1 (.1–2.7)  
 Oral rinse and gargle 7 13 698 4.0 (2.7–5.6)  1.6 (.6–2.9)  0.5 (.3–.8)  
 Brush/swab and oral rinse, gargle, or saliva 9 2824 5.3 (2.5–9.0)  5.0 (1.4–10.4)  0.8 (.0–2.6)  
Anatomic site    P-valuec = .481  P-valuec = .752  P-valuec = .183
 Oral mucosa 31 12 087 5.1 (3.5–7.1)  2.7 (1.5–4.3)  1.2 (.5–2.1)  
 Oral and oropharyngeal mucosa 15 16 087 4.3 (2.9–6.0)  2.5 (1.4–3.9)  0.7 (.3–1.1)  
Last year of testing    P-valuec = .663  P-valuec = .356  P-valuec = .142
 2006 22 9535 5.2 (3.3–7.4)  3.3 (1.4–5.9)  1.6 (.4–3.3)  
 2013 26 19 009 4.6 (3.2–6.3)  2.2 (1.3–3.3)  0.7 (.4–1.0)  
Age, y, mean    P-valuec = .003  P-valuec = .257  P-valuec = .367
 <25 11 4835 2.8 (1.8–3.9)  2.3 (.6–4.9)  0.8 (.2–1.9)  
 25–39 9 4889 8.6 (5.4–12.5)  4.9 (2.0–9.0)  1.8 (.3–4.2)  
 40–54 13 14 234 3.9 (1.7–6.8)  1.4 (.4–3.0)  0.4 (.2–.8)  
 >55 8 1597 6.5 (2.9–11.3)  2.1 (.3–5.1)  1.0 (.0–2.9)  
 Unknown 10 2989 4.7 (1.6–9.2)  4.1 (.9–9.1)  1.2 (.0–4.1)  
DNA assessment    P-valuec = .209  P-valuec = .314  P-valuec = .108
 Yes 38 24 190 4.5 (3.3–5.9)  2.3 (1.4–3.4)  0.8 (.4–1.2)  
 No 10 4354 6.5 (3.7–9.9)  3.6 (1.3–6.9)  2.1 (.4–4.7)  
>100 samples    P-valuec = .242  P-valuec = .848   
 Yes 40 26 634 5.2 (3.9–6.6)  2.6 (1.7–3.6)  1.0 (.6–1.5)  
 No 9 1910 3.1 (1.2–5.8)  2.4 (.6–5.1)  …  
Abbreviation: CI, confidence interval.
aData are for studies contributing data on the overall prevalence of oral HPV. Studies contributing data on oral high-risk HPV or HPV16 prevalences are not shown.
bData are for individuals tested for overall oral HPV. The number tested for oral high-risk HPV or HPV16 are not shown.
cFor heterogeneity between groups within the variable. Groups with <500 cases have been excluded.
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interactions between competing factors and determinants of 
clearance and persistence. Noteworthy, the gap between oral 
HPV infection and onset of HPV-related OPC may reach up 
to 20 years, and, thus, cohort effects may also play a role. A re-
cent systematic review of the incidence and clearance of oral 
HPV infection noted that estimates varied notably between re-
gions [39]. Previous data showed that male sex, older age, cur-
rent smoking [40], some medications with immunomodulatory 
effects [41], and HPV16 integration [42] may play a role in oral 
HPV persistence in healthy individuals.
When comparing oral HPV by region, differences in overall 
estimates were not statistically significant. However, regional 
differences were statistically significant for HPV16 estimates, 
with the highest prevalences observed in Europe and North 
America, in line with what is observed in OPC.
In the age-specific analysis, the highest prevalence was 
observed at ages >50  years (Figure 4), following a sigmoid 
curve. When we performed an alternative analysis using the 
mean age of the study population instead of age-specific preva-
lences (Table 1), we found a bimodal pattern, although most of 
the CIs overlapped, and in our view the age-specific prevalence 
provides a more-robust estimate.
We made a special effort to retrieve information on a large 
collection of potential determinants in each study, such as risk 
factors, study design, or technical details of specimen collection 
and HPV testing methods. In contrast to a previous meta-anal-
ysis [19], we did not observe an increased prevalence with time, 
despite observing increased time trends in HPV-related OPC 
in some regions of the world [3, 4, 11]. The long clinical latency 
between HPV infection and oncogenesis could explain such 
discrepancies. Although oral brush or swab samples were pre-
viously found to provide insufficient DNA quality as compared 
to oral rinse and gargle specimens [43–46], we did not observe 
a higher HPV prevalence in oral rinse or gargle specimens than 
in brush or swab samples. However, a large study evaluating 
HPV prevalence in tonsil brushings and gargle specimens in 
cancer-free patients suggested that gargle specimens are not 
representative of the HPV prevalence in the tonsil [46].
Although few studies presented data stratified by sex, to-
bacco use, alcohol use, and sexual behavior, we could pool RRs 
by using a random-effect model. Globally, only a high lifetime 
number of sex partners showed a significantly higher risk of 
oral HPV infection. However, this finding mainly came from 
North American studies. A  tendency of a higher risk of oral 
HPV infection was observed in ever smokers. We did not ob-
serve a higher RR of oral HPV infection among people with 
a history of performing oral sex as compared to those with no 
such history (Table 2), but oral HPV prevalences in studies with 
a higher proportion of individuals with a history of performing 
oral sex did show statistically significant higher prevalences 
Study Prev (95% Cl)
n = 8787 <30 y
21 studies Subtotal (I2 = 78.3%, P = .0)
n = 678 30-39 y
13 studies Subtotal (I2 = 37.0%, P = .1)
n = 659 40-49 y
12 studies Subtotal (I2 = 51.4%, P = .0)
n = 817 50-59 y
13 studies Subtotal (I2 = 45.3%, P = .0)
n = 551 ≥60 y
12 studies Subtotal (I2 = 51.6%, P = .0)
Heterogeneity between groups: P = .002
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(Table 1). A previous systematic review found that subjects with 
a history of tobacco use or performing oral sex had a signifi-
cantly increased risk of oral HPV infection [18]. Higher risks of 
oral HPV infection in smokers have also been observed in large 
population-based studies, such as the NHANES in the United 
States [35] or the HIM study in Brazil, Mexico, and the United 
States [47].
Our study had some limitations. The large variability in the 
methods of specimen collection and processing and the small 
sample sizes of the studies limited the unequivocal assessment 
of the prevalence of oral HPV in healthy population. High het-
erogeneity was observed in most analyses, although we strat-
ified by several covariates. However, the main strength of 
meta-analyses lies on their use as a comparative rather than a 
synthetic exercise [48], because statistical techniques cannot 
compensate for fundamental limitations of the input data but 
can help to identify patterns in study results and sources of het-
erogeneity. Another limitation was the unavailability of covari-
ate-specific prevalence data. Moreover, overall and type-specific 
information on HPV infection was unequally distributed across 
the globe, with certain regions, especially Africa and Oceania, 
contributing only a few studies, including small series. We did 
not assess DNA extraction method as a covariate, but D’Souza 
et  al found that different DNA purification methods showed 
different oral HPV prevalences [49]. A total of 34% of articles 
did not specify any recruitment period, and surrogate measures 
such as publication year could not be as precise as needed to 
assess time trends.
Our evaluation of the epidemiological landscape of oral 
HPV infection across different populations does not support 
that differences in HPV AFs in OPC could be explained by 
difference in oral HPV prevalence across healthy populations. 
Table 2. Relative Risk of Oral Human Papillomavirus Infection Due to Any Type, by Risk Factor
Risk Factor Studies, No. Variable Relative Risk (95% CI)
Sex  Male Female Male vs Female
 Global 34 13 090 11 410 1.2 (.74–1.9)
 Africa 3 289 193 0.7 (.1–7.1)
 Asia 5 3152 616 1.1 (.5–2.4)
 Europe 9 607 718 0.8 (.5–1.3)
 Latin America 7 1893 3528 1.3 (.5–3.5)
 North America 13 7149 6355 2.0 (1.0–4.0)a
Tobacco use  Yes No Yes vs No
Global 11 1566 2636 1.4 (.9–2.4)
 Africa 2 69 106 1.2 (.3–4.5)
 Asia 4 300 872 1.5 (.2–9.1)
 Europe 1 80 34 0.8 (.3–2.1)
 Latin America 0 … … …
 North America 5 430 673 1.6 (.6–4.0)
Alcohol use  Yes No Yes vs No
 Global 6 535 1286 1.3 (.7–2.4)
 Africa 2 112 63 1.3 (.2–11.5)
 Asia 4 158 1049 2.3 (.3–19.8)
 Europe 1 94 20 1.3 (.3–5.3)
 Latin America 0 … … …
 North America 1 171 154 1.1 (.4–3.0)
Oral sex performance  Yes No Yes vs No
 Global 8 2218 735 1.2 (.6–2.6)
 Africa 2 54 121 1.2 (.3–4.4)
 Asia 2 46 136 1.4 (.4–4.9)
 Europe … … … …
 Latin America 1 370 131 1.8 (.2–15.0)
 North America 3 445 215 1.4 (.2–14.2)
Lifetime no. of sex partners  High Low High vs Low
 Global 5 585 731 2.3 (1.3–3.9)
 Africa 1 9 3 …a
 Asia 1 2 4 …a
 Europe 1 13 75 1.7 (.6–5.5)
 Latin America 1 220 119 1.1 (.1–11.8)
 North America 3 341 530 2.6 (1.4–4.8)
Abbreviation: CI, confidence interval.
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There is a need for more-detailed information from large and 
well-designed studies to make definitive conclusions on the 
determinants of HPV AFs in OPC, since its assessment from 
aggregated reports is challenging and because assessment via 
average parameters is prone to ecological fallacy. New devel-
opments of screening techniques for HPV-related HNC call 
for the identification of high-risk populations, with a view to 
optimizing prevention [50]. Thus, consistent research on the 
determinants of the prevalence, acquisition, clearance, and 
persistence of oral HPV infection is warranted to fill the gaps 
in knowledge of the HPV-related natural history of OPC.
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Figure 5. Correlation between oral human papillomavirus type 16 (HPV16) infection and HPV-attributable fraction (AF) of oropharyngeal cancer (OPC) (A), age-standardized 
incidence rate (ASR) of HPV-associated head and neck cancer (HNC) (B), genital HPV16 infection in healthy women (C), and smoking prevalence (D), by country . Countries 
with outlying estimates were excluded. Estimates for HPV-AFs were derived from Castellsagué et al [12] for all regions except North America, Southern Africa, Northern 
Africa, and Australia and New Zealand AFs. For North America, AFs were derived from Jordan et al [32]; for Southern and Northern Africa, AFs were derived from de Martel 
et al [13]; and for Australia and New Zealand, AFs were derived from Hong et al [33]. Estimates of ASRs of HPV-related HNC in 2012 were derived from de Martel et al [13]. 
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